HPV- Human Papilloma Virus University of Pittsburgh Rövid összefoglaló This is a randomized, open label trial of HPV human papilloma virus vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose. All hasnyálmirigy-férgek gyógyszere would receive the first and second doses according to schedule.
They would be randomized to either vaccine at 6 months or vaccine at 12 months. Blood will be drawn for titers twice from all participants: pre-dose 1 and one month post third dose. Papillomavírusos lány Részletes leírás The recommendations for HPV vaccine include papillomavírus jab of women 18 to 26 years old.
Given that a large percentage of women in this age group are attending college, a good place to access them would be through the student health services on college campuses. However, the HPV vaccine schedule of 0, 2, and 6 months is likely to be difficult to implement in a college calendar year and the immunogenicity of alternative schedules is unknown.
If the immunogenicity of an altered schedule is good, then higher vaccination rates may papillomavírus jab achievable. Aims: 1. Determine if delay in the third dose is immunologically non-inferior to the standard administration schedule 1 month papillomavírus jab jab 3.
Determine the side effect profile of a delayed third dose, in comparison to the standard schedule Átfogó állapot.